FILE 'REGISTRY' ENTERED AT 12:23:28 ON 08 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006   HIGHEST RN 899508-12-4
DICTIONARY FILE UPDATES: 7 AUG 2006   HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

   Please note that search-term pricing does apply when
   conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10659091core.str

chain nodes :
6   7   8   9   10   11   12   13   14   15   16   18   20   21   22   24   25   27   28
ring nodes :
1   2   3   4   5
chain bonds :
3-6   4-11   5-15   5-16   6-7   6-28   7-21   8-9   8-22   9-10   10-24   11-12   12-13   13-14
 13-18   14-27   15-20   21-22   24-25
ring bonds :
1-2   1-5   2-3   3-4   4-5
exact/norm bonds :
1-2   1-5   2-3   3-4   4-5   5-15   10-24   12-13   13-14   13-18   14-27   15-20   24-25
exact bonds :
3-6   4-11   5-16   6-7   6-28   7-21   8-9   8-22   9-10   11-12   21-22

G1:O,S

G2:H,Ak

G3:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS

```
L1        STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:23:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        4 TO ITERATE

100.0% PROCESSED        4 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           4 TO       200
PROJECTED ANSWERS:              0 TO         0

L2              0 SEA SSS SAM L1

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



```
G1 O,S

G2 H,Ak

G3 O,N


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss full
FULL SEARCH INITIATED 12:24:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       50 TO ITERATE

100.0% PROCESSED       50 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

L3              0 SEA SSS FUL L1

=> log hold
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY        SESSION
FULL ESTIMATED COST                          167.38        167.59

  SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:24:45 ON 08 AUG 2006

Connecting via Winsock to STN
```

Welcome to STN International!   Enter x:x

LOGINID:SSPTAEX01623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 12:26:17 ON 08 AUG 2006
FILE 'REGISTRY' ENTERED AT 12:26:17 ON 08 AUG 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                              ENTRY   SESSION
FULL ESTIMATED COST   167.38   167.59

=>
Uploading C:\Program Files\Stnexp\Queries\10659091core2.str

chain nodes :
6   7   8   9   10   11   12   13   14   15   16   18   20   21   22   24   25   27   28   29   30   31
32   33   34   35
ring nodes :
1   2   3   4   5
chain bonds :

1-28 1-29 3-6 3-33 4-11 4-30 5-15 5-16 6-7 6-34 6-35 7-21 8-9 8-22
9-10 10-24 11-12 11-31 11-32 12-13 13-14 13-18 14-27 15-20 21-22 24-25
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-15 10-24 11-12 12-13 13-14 13-18 14-27 15-20
24-25
exact bonds :
1-28 1-29 3-6 3-33 4-11 4-30 5-16 6-7 6-34 6-35 7-21 8-9 8-22 9-10
11-31 11-32 21-22

G1:O,S

G2:H,Ak

G3:O,N

Match level :
1:Atom   2:Atom   3:Atom   4:Atom   5:Atom   6:CLASS   7:CLASS   8:CLASS   9:CLASS
10:CLASS   11:CLASS   12:CLASS   13:CLASS   14:CLASS   15:CLASS   16:CLASS   18:CLASS
20:CLASS   21:CLASS   22:CLASS   24:CLASS   25:CLASS   27:CLASS   28:CLASS   29:CLASS
30:CLASS   31:CLASS   32:CLASS   33:CLASS   34:CLASS   35:CLASS

L4   STRUCTURE UPLOADED

=> d 14
L4 HAS NO ANSWERS
L4   STR

G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 14
SAMPLE SEARCH INITIATED 12:26:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   4 TO ITERATE

100.0% PROCESSED   4 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:   ONLINE   **COMPLETE**
                         BATCH    **COMPLETE**
PROJECTED ITERATIONS:             4 TO        200
PROJECTED ANSWERS:                1 TO         80


L5              1 SEA SSS SAM L4

=> d l5 scan

L5   1 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-3-hydroxy-5-oxo-2-[[[[(2-
     phenylethyl)amino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)-(9CI)
MF   C22 H29 N O6

Absolute stereochemistry.
Double bond geometry as shown.
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


ALL ANSWERS HAVE BEEN SCANNED


=> s l4 sss full
FULL SEARCH INITIATED 12:27:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        50 TO ITERATE

100.0% PROCESSED        50 ITERATIONS                      25 ANSWERS
SEARCH TIME: 00.00.01

L6              25 SEA SSS FUL L4

=> d l6 scan

L6   25 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
     [[[(phenylamino)carbonyl]oxy]methyl]cyclopentyl]-, methyl ester, (5Z)-
     (9CI)
MF   C21 H29 N O6

Absolute stereochemistry.
Double bond geometry as shown.
```

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

```
L6    25 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN    5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
      [[[(phenylamino)carbonyl]oxy]methyl]cyclopentyl]-, (5Z)-(9CI)
MF    C20 H27 N O6
```

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
L6    25 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN    5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
      [[[[(phenylmethyl)amino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)-(9CI)
MF    C21 H29 N O6
```

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6   25 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R,5S)-2-[[[(butylamino)carbonyl]oxy]methyl]-
    3,5-dihydroxycyclopentyl]-, methyl ester, (5Z)- (9CI)
MF   C19 H33 N O6

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L6   25 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-
    [[[(phenylmethyl)amino]thioxomethoxy]methyl]cyclopentyl]-, (5Z)- (9CI)
MF   C21 H29 N O5 S

Absolute stereochemistry.
Double bond geometry as shown.

L6   25 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[(butylamino)thioxomethoxy]methyl]-3-
      hydroxy-5-oxocyclopentyl]-, (5Z)- (9CI)
MF   C18 H29 N O5 S

Absolute stereochemistry.
Double bond geometry as shown.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\Stnexp\Queries\10659091ketone.str

chain nodes :
6   7   8   9   10   11   12   13   14   15   16   18   20   21   22   24   25   27   28   29   30   31
32   33   34   35   36
ring nodes :
1   2   3   4   5
chain bonds :
1-28   1-29   2-36   3-6   3-33   4-11   4-30   5-15   5-16   6-7   6-34   6-35   7-21   8-9
8-22   9-10   10-24   11-12   11-31   11-32   12-13   13-14   13-18   14-27   15-20   21-22
24-25
ring bonds :
1-2   1-5   2-3   3-4   4-5
exact/norm bonds :
1-2   1-5   2-3   2-36   3-4   4-5   5-15   10-24   11-12   12-13   13-14   13-18   14-27
15-20   24-25
exact bonds :
1-28   1-29   3-6   3-33   4-11   4-30   5-16   6-7   6-34   6-35   7-21   8-9   8-22   9-10
11-31   11-32   21-22

G1:O,S

G2:H,Ak

G3:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS

L7   STRUCTURE UPLOADED

=> d 17
L7 HAS NO ANSWERS
L7   STR

G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 17
SAMPLE SEARCH INITIATED 12:28:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   3 TO ITERATE

100.0% PROCESSED   3 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 3 TO   163
PROJECTED ANSWERS: 1 TO   80

L8   1 SEA SSS SAM L7

=> d 18 scan

L8   1 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-3-hydroxy-5-oxo-2-[[[[(2-
     phenylethyl)amino]carbonyl]oxy]methyl]cyclopentyl]-, (5Z)- (9CI)
MF   C22 H29 N O6

Absolute stereochemistry.
Double bond geometry as shown.

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

ALL ANSWERS HAVE BEEN SCANNED

=> s 17 sss full·
FULL SEARCH INITIATED 12:28:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   38 TO ITERATE

100.0% PROCESSED   38 ITERATIONS   6 ANSWERS
SEARCH TIME: 00.00.01

L9   6 SEA SSS FUL L7

=> d 19 scan

L9   6 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[(butylamino)thioxomethoxy]methyl]-3-
      hydroxy-5-oxocyclopentyl]-, methyl ester, (5Z)- (9CI)
MF   C19 H31 N O5 S

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L9   6 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[(butylamino)thioxomethoxy]methyl]-3-
      hydroxy-5-oxocyclopentyl]-, (5Z)- (9CI)
MF   C18 H29 N O5 S

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9   6 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[[(butylamino)carbonyl]oxy]methyl]-3-
       hydroxy-5-oxocyclopentyl]-, methyl ester, (5Z)- (9CI)
MF   C19 H31 N O6

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9   6 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R)-2-[[[(butylamino)carbonyl]oxy]methyl]-3-
       hydroxy-5-oxocyclopentyl]-, (5Z)- (9CI)
MF   C18 H29 N O6

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	503.02	503.23

FILE 'CAPLUS' ENTERED AT 12:29:55 ON 08 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 8 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 7 Aug 2006 (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l9
L10   1 L9

=> d l10

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN   2005:220145 CAPLUS
DN   142:297917
TI   Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-
     heptan(en)oic acid compounds for treating ocular hypertension
IN   Old, David W.; Burk, Robert M.
PA   Allergan, Inc., USA
SO   U.S. Pat. Appl. Publ., 12 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1

```
        PATENT NO.              KIND   DATE        APPLICATION NO.              DATE
        ---------------         ----   --------    ---------------------       --------
PI   US 2005054689              A1     20050310    US 2003-659091              20030909
     AU 2004272524              A1     20050324    AU 2004-272524              20040818
     CA 2537794                 AA     20050324    CA 2004-2537794             20040818
     WO 2005026109              A1     20050324    WO 2004-US27001             20040818
        W:   AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1663961                 A1     20060607    EP 2004-781645              20040818
        R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRAI US 2003-659091             A      20030909
     WO 2004-US27001            W      20040818
OS   CASREACT 142:297917; MARPAT 142:297917


=> file registry
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY       SESSION
FULL ESTIMATED COST                               1.60        504.83
```

FILE 'REGISTRY' ENTERED AT 12:30:30 ON 08 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006   HIGHEST RN 899508-12-4
DICTIONARY FILE UPDATES: 7 AUG 2006   HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

   Please note that search-term pricing does apply when
   conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10659091halogen.str

chain nodes :
6   7   8   9   10   11   12   13   14   15   16   18   20   21   22   24   25   27   28   29   30   31
32   33   34   35   36   37
ring nodes :
1   2   3   4   5
chain bonds :
1-28   1-29   2-36   3-6   3-33   4-11   4-30   5-15   5-16   6-7   6-34   6-35   7-21   8-9
8-22   9-10   10-24   11-12   11-31   11-32   12-13   13-14   13-18   14-27   15-20   21-22
24-25   36-37
ring bonds :
1-2   1-5   2-3   3-4   4-5
exact/norm bonds :
1-2   1-5   2-3   3-4   4-5   5-15   10-24   11-12   12-13   13-14   13-18   14-27   15-20
24-25
exact bonds :
1-28   1-29   2-36   3-6   3-33   4-11   4-30   5-16   6-7   6-34   6-35   7-21   8-9   8-22
9-10   11-31   11-32   21-22   36-37

G1:O,S

G2:H,Ak

G3:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS
20:CLASS 21:CLASS 22:CLASS 24:CLASS 25:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS

L11   STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11   STR

G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l11
SAMPLE SEARCH INITIATED 12:31:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1 TO ITERATE

100.0% PROCESSED   1 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1 TO   80
PROJECTED ANSWERS: 0 TO   0

L12   0 SEA SSS SAM L11

=> s l11 sss full
FULL SEARCH INITIATED 12:31:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   4 TO ITERATE

100.0% PROCESSED   4 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

L13   0 SEA SSS FUL L11

=> d his

```
                (FILE 'HOME' ENTERED AT 12:23:15 ON 08 AUG 2006)

        FILE 'REGISTRY' ENTERED AT 12:23:28 ON 08 AUG 2006
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            0 S L1 SSS FULL
L4              STRUCTURE UPLOADED
L5            1 S L4
L6           25 S L4 SSS FULL
L7              STRUCTURE UPLOADED
L8            1 S L7
L9            6 S L7 SSS FULL


        FILE 'CAPLUS' ENTERED AT 12:29:55 ON 08 AUG 2006
L10           1 S L9


        FILE 'REGISTRY' ENTERED AT 12:30:30 ON 08 AUG 2006
L11             STRUCTURE UPLOADED
L12           0 S L11
L13           0 S L11 SSS FULL

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                               ENTRY       SESSION
FULL ESTIMATED COST                           167.38       672.21

STN INTERNATIONAL LOGOFF AT 12:31:54 ON 08 AUG 2006
```

=>
Uploading C:\Program Files\Stnexp\Queries\10659091ketone2.str

L1   STRUCTURE UPLOADED

=> ld l1
LD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l1
L1 HAS NO ANSWERS
L1   STR

G1 O,S

G2 H,Ak

G3 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:07:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6 TO ITERATE

100.0% PROCESSED   6 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                         BATCH   **COMPLETE**
PROJECTED ITERATIONS: 6 TO   266
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:07:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   60 TO ITERATE

100.0% PROCESSED   60 ITERATIONS   2 ANSWERS
SEARCH TIME: 00.00.01

L3   2 SEA SSS FUL L1

=> d l3 scan

L3   2 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R,5R)-2-[[[(butylamino)carbonyl]oxy]methyl]-5-
     chloro-3-hydroxycyclopentyl]-, (5Z)-(9CI)
MF   C18 H30 Cl N O5

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3   2 ANSWERS   REGISTRY COPYRIGHT 2006 ACS on STN
IN   5-Heptenoic acid, 7-[(1R,2S,3R,5R)-2-[[[(butylamino)carbonyl]oxy]methyl]-5-
     chloro-3-hydroxycyclopentyl]-, methyl ester, (5Z)-(9CI)
MF   C19 H32 Cl N O5

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE        TOTAL
                                               ENTRY         SESSION
FULL ESTIMATED COST                           166.94         167.15
```

```
=> s 13
L4            1 L3

=> d 13
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n


=> d 14 ti abs bib

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of 2-(thiocarbamoyloxy)- and 2-(carbamoyloxy)cyclopentane-1-
     heptan(en)oic acid compounds for treating ocular hypertension
GI
```

$$I$$

$$III$$

AB   A method of treating ocular hypertension (glaucoma) comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula (I) [wherein a wavy segments indicate either the α or β configuration; the dashed bond represents a double bond or a single bond; U = :O, α- or β-halo; Z = O, S; Ar = (un)substituted C4-10 aryl or heteroaryl; n = 0-4; x, y = 0, 1; provided that when x is 1, yr is 0 and when x is 0, yr is 1; R1 = H, (un)substituted C≤6 alkyl; X = OR1, N(R1)2; Y = :O or represents 2 hydrogen radicals] or pharmaceutically acceptable salts and/ or esters thereof. Thus, carbamoylation of (Z)-7-[(1R,2S,3R,5S)-2-(hydroxymethyl)-3,5-bis(tetrahydropyran-2-yloxy)cyclopentyl]hept-5-enoic acid Me ester with Bu isocyanate in the presence of DABCO in THF followed by treatment with pyridinium p-toluenesulfonate in MeOH gave (Z)-7-[(1R,2S,3R,5S)-2-[(butylcarbamoyloxy)methyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Me ester which was silylated with tert-butyldimethylsilyl chloride in the presence of Et3N and 4-dimethylaminopyridine in CH2Cl2 to give (Z)-7-[(1R,2S,3R,5S)-2-[(butylcarbamoyloxy)methyl]-3-(tert-butyldimethylsilyloxy)-5-hydroxycyclopentyl]hept-5-enoic acid Me ester (II). Oxidation of II with tetrapropylammonium perruthenate, 4-methylmorpholine N-oxide, and 4Å mol. sieves in CH2Cl2 to give (Z)-7-[(1R,2S,3R)-2-[(butylcarbamoyloxy)methyl]-3-(tert-butyldimethylsilyloxy)-5-oxocyclopentyl]hept-5-enoic acid Me ester which was treated with HF-pyridine in MeCN to give (Z)-7-[(1R,2S,3R)-2-[(butylcarbamoyloxy)methyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoic acid Me ester (III).

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005054689	A1	20050310	US 2003-659091	20030909
AU 2004272524	A1	20050324	AU 2004-272524	20040818
CA 2537794	AA	20050324	CA 2004-2537794	20040818
WO 2005026109	A1	20050324	WO 2004-US27001	20040818

        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

```
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
     EP 1663961          A1    20060607    EP 2004-781645          20040818
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRAI US 2003-659091       A    20030909
     WO 2004-US27001      W    20040818
OS   CASREACT 142:297917; MARPAT 142:297917


=> d his

     (FILE 'HOME' ENTERED AT 13:06:48 ON 08 AUG 2006)

     FILE 'REGISTRY' ENTERED AT 13:06:55 ON 08 AUG 2006
L1              STRUCTURE UPLOADED
L2          0 S L1
L3          2 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:07:40 ON 08 AUG 2006
L4          1 S L3
```

```
INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
      AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
      CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
      ·DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:07:14 ON 08 AUG 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s ((prostaglandin(w)e2) or PGE2) and (ocular(w)hypertension)
'E2' NOT FOUND
The E# entered is not currently defined.

=> s ((prostaglandin(w)'E2') or PGE2) and (ocular(w)hypertension)
          1    FILE ADISCTI
         13    FILE BIOSIS
          1    FILE BIOTECHABS
          1    FILE BIOTECHDS
          1    FILE BIOTECHNO
         27    FILE CAPLUS
          3    FILE DDFU
          3    FILE DGENE
    23 FILES SEARCHED...
          4    FILE DRUGU
         17    FILE EMBASE
         28    FILE IFIPAT
          1    FILE IMSRESEARCH
          6    FILE JICST-EPLUS
         15    FILE MEDLINE
          3    FILE PASCAL
          1    FILE PHAR
    51 FILES SEARCHED...
          1    FILE PROMT
          5    FILE PROUSDDR
          4    FILE SCISEARCH
         15    FILE TOXCENTER
         39    FILE USPATFULL
          4    FILE USPAT2
         25    FILE WPIDS
         25    FILE WPINDEX
          6    FILE DPCI
         59    FILE EPFULL
    73 FILES SEARCHED...
          1    FILE IMSPATENTS
          5    FILE INPADOC
    79 FILES SEARCHED...
        139    FILE PCTFULL
    87 FILES SEARCHED...

    29 FILES HAVE ONE OR MORE ANSWERS,    92 FILES SEARCHED IN STNINDEX

L1   QUE ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION)

=> file biosis medline embase uspatfull epfull pctfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                              ENTRY         SESSION
FULL ESTIMATED COST                           3.05           3.26

FILE 'BIOSIS' ENTERED AT 14:10:03 ON 08 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 14:10:03 ON 08 AUG 2006
```

```
=> s ((prostaglandin(w)'E2') or PGE2)´and (ocular(w)hypertension)
L2          282 ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION)

=> s l2 not py>2002
L3          161 L2 NOT PY>2002

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4          146 DUP REM L3 (15 DUPLICATES REMOVED)

=> d l4 1-30 ti
```

L4   ANSWER 1 OF 146 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
      STN   DUPLICATE 1
TI   Omega-cycloalkyl 17-heteroaryl prostaglandin E2
      analogs as EP2-receptor agonists.

L4   ANSWER 2 OF 146 USPATFULL on STN
TI   Ophthalmic compositions for treating ocular
        hypertension

L4   ANSWER 3 OF 146 USPATFULL on STN
TI   Combinations of prostaglandins and brimonidine or derivatives thereof

L4   ANSWER 4 OF 146 USPATFULL on STN
TI   Prostaglandin agonists and their use to treat bone disorders

L4   ANSWER 5 OF 146 USPATFULL on STN
TI   Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl
        derivatives as therapeutic agents

L4   ANSWER 6 OF 146 USPATFULL on STN
TI   Upregulation of endogenous prostaglandins to lower intraocular pressure

L4   ANSWER 7 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN   SUSTAINED RELEASE PREPARATIONS OF PHYSIOLOGICALLY ACTIVE COMPOUND HARDLY
        SOLUBLE IN WATER AND PRODUCTION PROCESS AND USE OF THE SAME.
TIFR   PREPARATIONS A LIBERATION LENTE CONTENANT UN COMPOSE PHYSIOLOGIQUEMENT
        ACTIF PEU SOLUBLE DANS L'EAU ET METHODE DE PRODUCTION ET D'UTILISATION
        DESDITES PREPARATIONS.
TIDE   ZUSAMMENSETZUNGEN ZUR VERZOeGERTEN ABGABE VON PHYSIOLOGISCH AKTIVEN
        VERBINDUNGEN DIE KAUM WASSERLOeSSLICH SIND, VERFAHREN ZU DEREN
        HERSTELLUNG UND DEREN VERWENDUNG.

L4   ANSWER 8 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN   CYCLOPENTAN(EN)OIC ACID, 2-ALKENYL DERIVATIVES AS THERAPEUTIC AGENTS IN
        THE TREATMENT OF OCULAR HYPERTENSION.
TIFR   DERIVES D'ACIDE CYCLOPENTAN(EN)O QUE, 2-ALCENYLE UTILISES EN TANT
        QU'AGENTS THERAPEUTIQUES DANS LE TRAITEMENT DE L'HYPERTENSION OCULAIRE.
TIDE   CYCLOPENTAN(EN)SAeURE-2-ALKENYL-DERIVATE ALS THERAPEUTIKA IN DER
        BEHANDLUNG DER OKULAeREN HYPERTONIE.

L4   ANSWER 9 OF 146 EPFULL COPYRIGHT 2006 EPO/FIZ KA on STN

TIEN   CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS
        THERAPEUTIC AGENTS.
TIFR   DERIVES 2-HETEROARYLALCENYL DE L'ACIDE CYCLOPENTANE HEPTAN(EN)OIQUE
        UTILISES COMME AGENTS THERAPEUTIQUES.
TIDE   CYCLOPENTANE HEPTAN(ENE)SAeURE, 2-HETEROARYLALKENYLDERIVATE ALS
        THERAPEUTISCHES MITTEL.

L4   ANSWER 10 OF 146 EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN   CYCLOPENTANE HEPTANOIC OR HEPTENOIC ACID, 2-ARYLALKYL OR ARYLALKENYL AND
        DERIVATIVES AS THERAPEUTIC AGENTS.
TIFR   ACIDE HEPTANOIQUE OU HEPTENOIQUE CYCLOPENTANIQUE, 2-ARYLALKYLE OU
        ARYLALCENYLE ET DERIVES DE CES DERNIERS UTILISES COMME AGENTS
        THERAPEUTIQUES.
TIDE   2-AZYLALKYL-ODER ARYLALENYL-CYCLOPENTANHEPTAN-UND HEPTENSAeUREN,
        DERIVATE UND THERAPEUTISCHE ANWENDUNG.

L4   ANSWER 11 OF 146 EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN   NOVEL 7-(5-SUBSTITUTED CYCLOPENTYL) AND (5-SUBSTITUTED CYCLOPENTENYL)
        HEPTYL ALCOHOLS, HEPTYLAMINES AND HEPTANOIC ACID AMINES, AND METHOD OF
        LOWERING INTRAOCULAR PRESSURE IN THE EYE OF A MAMMAL BY ADMINISTRATION
        OF THESE NOVEL COMPOUNDS.
TIFR   NOUVEAUX ALCOOLS DE 7-(CYCLOPENTYL SUBSTITUE EN POSITION 5) ET
        (CYCLOPENTENYL SUBSTITUE EN POSITION 5)-HEPTYLE, HEPTYLAMINES ET AMIDES
        D'ACIDE HEPTANOIQUE, ET PROCEDE DE REDUCTION DE LA PRESSION
        INTRA-OCULAIRE CHEZ UN MAMMIFERE PAR L'ADMINISTRATION DE CES NOUVEAUX
        COMPOSES.
TIDE   7-(5-SUBSTITUIERTES ZYKLOPENTYL) UND (5-SUBSTITUIERTES ZYKLOPENTYL)
        HEPTYL-ALKOHOL, HEPTYLAMINE UND HEPTAN-SAeURE-AMIDE UND DAS VERFAHREN
        ZUR SENKUNG DES AUGENINNENDRUCKS BEI SAeUGETIEREN DURCH ANWENDUNG DIESER
        NEUEN VERBINDUNGEN.

L4   ANSWER 12 OF 146 EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN   Prostaglandin derivatives for the treatment of glaucoma or
        ocular hypertension.
TIFR   Derives de prostaglandine pour traitement du glaucome ou hypertension
        oculaire.
TIDE   Prostaglandinderivate zur Behandlung des gruenen Stars oder einer
        okularen Hypertension.

L4   ANSWER 13 OF 146 PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR
        LOWERING INTRAOCULAR PRESSURE
TIFR   DERIVES D'ACIDE 3, 7 OU 3 ET 7 THIA OU OXA PROSTANOIQUE UTILISES COMME
        AGENTS POUR REDUIRE LA PRESSION INTRAOCULAIRE

L4   ANSWER 14 OF 146 PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   CYCLOPENTANE HEPTAN (ENE) ACYL SULFONAMIDE, 2-ALKYL OR 2-ARYLALKYL, OR
        2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
TIFR   DERIVES DE CYCLOPENTANE HEPTAN(ENE) ACYLE SULFONAMIDE, 2-ALKYLE OU
        2-ARYLALKYLE, OU 2-HETEROARYLALCENYLE EN TANT QU'AGENTS THERAPEUTIQUES

L4   ANSWER 15 OF 146 PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   HYPOTENSIVE LIPID AND TIMOLOL COMPOSITIONS AND METHODS OF USING SAME
TIFR   COMPOSITIONS A BASE DE TIMOLOL ET DE LIPIDE HYPOTENSEUR ET METHODES
        D'UTILISATION ASSOCIEES

L4   ANSWER 16 OF 146 PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
TIFR   DERIVES D'ACIDE PROTANOIQUE UTILISES EN TANT QU'AGENTS D'ABAISSEMENT DE
        LA PRESSION INTRAOCULAIRE

L4   ANSWER 17 OF 146 PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   METHOD FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA
TIFR   METHODE DE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME

```
L4      ANSWER 18 OF 146   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR
        LOWERING INTRAOCULAR PRESSURE
TIFR    DERIVES D'ACIDES PROSTANOIQUES 3, 7 OU 3 ET 7 THIA OU OXA UTILISES COMME
        AGENTS PERMETTANT DE BAISSER LA TENSION INTRAOCULAIRE

L4      ANSWER 19 OF 146   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    ENZYMES
TIFR    ENZYMES

L4      ANSWER 20 OF 146   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    ENZYMES
TIFR    ENZYMES

L4      ANSWER 21 OF 146   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    COMBINATION THERAPY FOR LOWERING AND CONTROLLING INTRAOCULAR PRESSURE
TIFR    THERAPIE COMBINEE ABAISSANT ET REGULANT LA TENSION INTRAOCULAIRE

L4      ANSWER 22 OF 146   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY DERIVATIVES OF
        CYCLOPENTYL-HEPTAN(ENE)OIC ACID AS THERAPEUTIC AGENTS
TIFR    DERIVES 2-THIOCARBAMOYLOXY ET 2-CARBAMOYLOXY D'ACIDE
        CYCLOPENTYL-HEPTAN(ENE)OIQUE EN TANT QU'AGENTS THERAPEUTIQUES

L4      ANSWER 23 OF 146   PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN    CYCLOPENTANE DERIVATIVES AS THERAPEUTIC AGENTS
TIFR    DERIVES DE CYCLOPENTANE UTILISES COMME AGENTS THERAPEUTIQUES

L4    ANSWER 24 OF 146   USPATFULL on STN
TI      Combinations of prostaglandins and brimonidine or derivatives thereof

L4    ANSWER 25 OF 146   USPATFULL on STN
TI      Method of enhancing hair growth

L4      ANSWER 26 OF 146   EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN    METHOD FOR EFFECTING VASODILATION WITH (1,5-INTER)ARYL PROSTAGLANDIN
        DERIVATIVES.
TIFR    METHODE DE VASODILATATION A L'AIDE DE DERIVES DE (1,5-INTER)ARYL-
        PROSTAGLANDINE.
TIDE    METHODE ZUR GEFAeSSERWEITERUNG MIT (1,5-INTER)ARYLPROSTAGLANDINDERIVATEN
        .

L4      ANSWER 27 OF 146   EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN    CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS
        THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR
        HYPERTENSION.
TIFR    UTILISATION DE DERIVES D'ACIDE CYCLOPENTANE HEPTAN(ENE)OIQUE,
        2-HETEROARYLALKENYLE EN TANT QU'AGENTS THERAPEUTIQUES POUR LE TRAITEMENT
        DE L'HYPERTENSION OCULAIRE.
TIDE    2-HETEROARYLALKENYLDERIVATE DER CYCLOPENTANO-HEPTAN(HEPTAEN)SAeURE ALS
        THERAPEUTISCHES MITTEL ZUR BEHANDLUNG DES ERHOeHTEN AUGENINNENDRUCKES.

L4      ANSWER 28 OF 146   EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN    EP2-RECEPTOR AGONISTS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE.
TIFR    AGONISTES DE RECEPTEUR EP2 UTILISES COMME AGENTS FAISANT BAISSER LA
        TENSION INTRAOCULAIRE.
TIDE    EP2-REZEPTORAGONISTEN ALS MITTEL ZUR SENKUNG DES AUGENINNENDRUCKS.

L4      ANSWER 29 OF 146   EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
TIEN    USE OF 9-DEOXY PROSTAGLANDIN DERIVATIVES TO TREAT GLAUCOMA.
TIFR    UTILISATION DE DERIVES DE LA 9-DESOXY PROSTAGLANDINE POUR TRAITER LE
        GLAUCOME.
TIDE    VERWENDUNG VON 9-DEOXYPROSTAGLANDINDERIVATEN ZUR BEHANDLUNG VON GLAUKOM.

L4      ANSWER 30 OF 146   EPFULL   COPYRIGHT 2006 EPO/FIZ KA on STN
```

TIEN   NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL
        DERIVATIVES AS THERAPEUTIC AGENTS.
TIFR   DERIVES NON-ACIDES DE 2-CYCLOALKYLE OU D'ARYLALKYLE D'ACIDE HEPTANOIQUE
        DE CYCLOPENTANE EN TANT QU'AGENTS THERAPEUTIQUES.
TIDE   2-ZYKLOALKYL-ODER ARYLALKYL-DERIVATE VON NICHT-SAeURE,
        ZYKLOPENTANE-HEPTANOIC-SAeURE.

=> file registry
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                 ENTRY   SESSION
FULL ESTIMATED COST   7.49   10.75

FILE 'REGISTRY' ENTERED AT 14:11:39 ON 08 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2006   HIGHEST RN 899508-12-4
DICTIONARY FILE UPDATES: 7 AUG 2006   HIGHEST RN 899508-12-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

    Please note that search-term pricing does apply when
    conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s PGE2/cn
L5   1 PGE2/CN

=> d l5

L5   ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN   363-24-6 REGISTRY
ED   Entered STN: 16 Nov 1984
CN   Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-,
      (5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-
      (8CI)
CN   5-Heptenoic acid, 7-[3α-hydroxy-2-(3-hydroxy-1-octenyl)-5-
      oxocyclopentyl]- (7CI)
OTHER NAMES:
CN   (-)-Prostaglandin E2
CN   (15S)-Prostaglandin E2
CN   11α,15α-Dihydroxy-9-ketoprosta-5,13-dienoic acid
CN   11α,15α-Dihydroxy-9-oxo-5-cis,13-trans-prostadienoic acid
CN   Cervidil
CN   Cerviprime
CN   Cerviprost
CN   Dinoprostone
CN   Enzaprost E
CN   Glandin
CN   1-PGE2

CN   1-Prostaglandin E2
CN   Minprositin E2
CN   Minprostin E2
CN   NSC 165560
CN   NSC 196514
CN   PGE2
CN   Prepidil
CN   Primiprost
CN   Propess
CN   Prostaglandin E2
CN   Prostarmon E
CN   Prostenon
CN   Prostenone
CN   Prostin
CN   Prostin (prostaglandin)
CN   Prostin E2
CN   U 12062
FS   STEREOSEARCH
MF   C20 H32 O5
CI   COM
LC   STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
        CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
        CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
        IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PROMT, PS, RTECS*,
        SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
           (*File contains numerically. searchable property data)
        Other Sources: EINECS**, WHO
           (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.
Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

        26746 REFERENCES IN FILE CA (1907 TO DATE)
          128 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
        26777 REFERENCES IN FILE CAPLUS (1907 TO DATE)
            1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                ENTRY   SESSION
FULL ESTIMATED COST   7.10   17.85

FILE 'CAPLUS' ENTERED AT 14:11:58 ON 08 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available

FILE COVERS 1907 - 8 Aug 2006   VOL 145 ISS 7
FILE LAST UPDATED: 7 Aug 2006   (20060807/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l5 and (ocular(w)hypertension)
        26777 L5
        16660 OCULAR
        80052 HYPERTENSION
          797 OCULAR(W)HYPERTENSION
L6         13 L5 AND (OCULAR(W)HYPERTENSION)

=> s l6 not py>2002
      4166028 PY>2002
L7         13 L6 NOT PY>2002

=> d l7 1-13 ti
```

L7   ANSWER 1 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   14-Aza prostaglandins for the treatment of glaucoma and ocular
     hypertension

L7   ANSWER 2 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Cyclobutane prostaglandin analogs as ocular hypotensive agents

L7   ANSWER 3 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Combinations of prostaglandins and clonidine derivatives for the treatment
     of glaucoma

L7   ANSWER 4 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Antagonist of platelet-activating factor prevents prostaglandin E2 induced
     ocular hypertension in rabbits

L7   ANSWER 5 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent
     therapeutic advantages of derived prostaglandins of the A and B type as
     compared with primary prostaglandins of the E, F and D type

L7   ANSWER 6 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Use of eicosanoids and their derivatives for treatment of ocular
     hypertension and glaucoma

L7   ANSWER 7 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Effect of β-adrenoblockers on prostaglandin-induced ocular
     hypertension in rabbits

L7   ANSWER 8 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   Long-term maintenance of reduced intraocular pressure by daily or twice
     daily topical application of prostaglandins to cat or rhesus monkey eyes

L7   ANSWER 9 OF 13   CAPLUS   COPYRIGHT 2006 ACS on STN
TI   A comparison of the miotic and inflammatory effects of biologically active
     polypeptides and prostaglandin E2 on the rabbit eye

TI   Effect of dipyridamole on prostaglandin-induced ocular
      hypertension in rabbits

L7   ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI   Consensual ocular hypertensive responses to prostaglandin E2

L7   ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI   Consensual ocular hypertensive response to prostaglandin

L7   ANSWER 13 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI   Mechanism of the antagonism of experimentally induced ocular
      hypertension by polyphloretin phosphate

=> d l7 3 5 6 8 9 ti abs bib

L7   ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI   Combinations of prostaglandins and clonidine derivatives for the treatment
      of glaucoma
AB   Combinations of ≥1 clonidine derivative (Markush included) and
      ≥1 prostaglandin are used to treat glaucoma and ocular
      hypertension without some of the side effects typically associated
      with topical administration of prostaglandins (no data).
AN   1994:418080 CAPLUS
DN   121:18080
TI   Combinations of prostaglandins and clonidine derivatives for the treatment
      of glaucoma
IN   Desantis, Louis, Jr.; Sallee, Verney L.
PA   Alcon Laboratories, Inc., USA
SO   PCT Int. Appl., 19 pp.
      CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9408585	A1	19940428	WO 1993-US9742	19931012
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9453286	A1	19940509	AU 1994-53286	19931012
AU 674038	B2	19961205		
EP 664707	A1	19950802	EP 1993-923372	19931012
EP 664707	B1	19970604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 153855	E	19970615	AT 1993-923372	19931012
ES 2105333	T3	19971016	ES 1993-923372	19931012
JP 3002258	B2	20000124	JP 1994-510215	19931012
JP 08502485	T2	19960319		
CA 2146127	C	20000613	CA 1993-2146127	19931012
US 5480900	A	19960102	US 1995-422570	19950410
US 5605922	A	19970225	US 1995-571326	19951212
US 5811443	A	19980922	US 1997-803667	19970221
PRAI US 1992-960065	A	19921013		
WO 1993-US9742	W	19931012		
US 1994-213380	B1	19940314		
US 1995-422570	A1	19950410		
US 1995-571326	A1	19951212		

OS   MARPAT 121:18080

L7   ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI   Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent
      therapeutic advantages of derived prostaglandins of the A and B type as
      compared with primary prostaglandins of the E, F and D type
AB   A and B prostaglandins (PGs) which are derived from PGs of the E type by

dehydration and isomerization, have a much greater ocular hypotensive
potency than the primary PGs of the E, F, or D type. A single application
of 5 µg PGA2 to the cat eye in a 25-µL volume of aqueous vehicle solution
yielded a greater and more prolonged ocular hypotensive effect than as
much as 100 µg of topically applied PGF2α. As little as 1 µg
of PGA2 had an ocular hypotensive effect that was enhanced by ≥3
consecutive daily applications of the same dose. This intraocular
pressure reduction, which remained for several days after the last of 10 daily
treatments, was not associated with biomicroscopically detectable flare or
invasion of the anterior chamber by cells. Although PFG2α and, to a
much lesser extent, PGE2 have a miotic effect in cats, PGs of the A and B
type did not cause miosis even at doses 50-100-fold greater than the min.
dose required to yield ocular hypotension. PGA2 retained its ocular
hypotensive potency when stored in an aqueous solution at room temperature for
4 mo.
The conjunctival hyperemia caused by 5 or 10 µg A or B type PGs on
rabbit eyes was milder and shorter in duration than that caused by the
same doses of PGE2 or PGF2α. Thus, derived PGs, especially PGs of the A
type, may have a therapeutic advantage over primary PGs for the treatment
of ocular hypertension and glaucoma.

AN	1987:509969 CAPLUS
DN	107:109969
TI	Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent therapeutic advantages of derived prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D type
AU	Bito, Laszlo Z.; Baroody, Roger A.; Miranda, Olivia C.
CS	Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
SO	Experimental Eye Research (1987), 44(6), 825-37
	CODEN: EXERA6; ISSN: 0014-4835
DT	Journal
LA	English

|	
L7	ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
AB	Ocular hypertension and glaucoma can be effectively controlled through topical application of an effective amount of an eicosanoid or an eicosanoid derivative to the surface of an afflicted eye. PGE2 [363-24-6] and PGF2α [551-11-1], and derives thereof, were effective in quantities <100 µg/eye. For example, the relative intraocular hypotensive potencies of prostaglandins that yielded intraocular pressure reduction of ≥5 mm Hg 6 h after topical application to cats were: PGF2α Me ester [33854-16-9] » PGE2 > PGF2α tromethamine salt [38562-01-5] > PGF2α.
AN	1984:115579 CAPLUS
DN	100:115579
TI	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
IN	Bito, Laszlo Z.
PA	Columbia University, USA
SO	Eur. Pat. Appl., 36 pp.
	CODEN: EPXXDW
DT	Patent
LA	English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	---------------	----	--------	--------------------	--------
PI	EP 93380	A2	19831109	EP 1983-104083	19830426
	EP 93380	A3	19840328		
	EP 93380	B1	19870114		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4599353	A	19860708	US 1982-374165	19820503
	AU 560189	B2	19870402	AU 1983-13916	19830426
	JP 59001418	A2	19840106	JP 1983-76053	19830428
	JP 04068288	B4	19921102		

TI   Long-term maintenance of reduced intraocular pressure by daily or twice
     daily topical application of prostaglandins to cat or rhesus monkey eyes
GI

AB   Intraocular pressure (IOP) reduction was maintained in cats for up to 9 mo by
     topical application of PGE2 (I) [363-24-6] at 12-, 24-, or 48-h
     intervals. The IOP reduction was jeopardized seriously only when I was
     applied every other day for several days or when, on a few occasions, 3
     days were allowed to elapse between I applications. Ocular hypotension
     was also maintained during the course of topical treatment of rhesus
     monkey eyes with PGF2α [551-11-1]. Short periods of pupillary
     constriction followed the application of each dose of PGF2α to cat
     eyes, but the miotic response of rhesus monkeys to PGF2α and cats to
     I was negligible. Other apparent side effects were noted, but none of
     these were severe or progressive. Thus, tachyphylaxis, or tolerance, is
     not expected to present an obstacle to the development of eicosanoids
     and(or) their derivs. as therapeutic agents for the long-term treatment of
     ocular hypertension and chronic glaucoma.

TI   A comparison of the miotic and inflammatory effects of biologically active
     polypeptides and prostaglandin E2 on the rabbit eye
GI

AB   The ocular effects of some biol. active peptides were studied and compared
     to those of PGE2 (I) [363-24-6] to determine whether the responses
     of the eye to trauma, characterized by increased intraocular pressure

(IOP), the development of anterior chamber flare, and partial miosis, might be mediated by such peptides. At 1-2 h after intravitreal injection of 10 μg of I into rabbit eyes, ocular hypertension
, flare, and iridial hyperemia, but only minimal miosis were observed Maximum miosis developed within 2-3 h after intravitreal injection of 1.0-100 μg of substance P (SP) [33507-63-0], SP-octapeptide (SP-8) [53749-60-3], coherin [9044-70-6], or eledoisin-related peptide (EDR) [2990-43-4], whereas 10-100 μg of VIP [37221-79-7], somatostatin [51110-01-1], or bradykinin (BK) [58-82-2] yielded only submaximal miosis and angiotensin II [11128-99-7], α-MSH [37213-49-3], and poly-DL-alanine [25281-63-4] had little or no miotic effect. None of these peptides caused iridial hyperemia or a cellular invasion of the anterior chamber and only high doses (100 μg) of VIP or BK caused significant increases in the protein concentration of the aqueous humor. Miotic doses of SP, SP-8, or EDR caused a significant increase in IOP in some, but not all, expts. Thus, I can be regarded as a mediator of the ocular irritative response although it may not account for the miosis that is associated with chemical or surgical trauma. In contrast, some polypeptides, particularly SP, SP-8, and EDR are strong miotics and, at least under some circumstances, can act as effective ocular hypertensives, but these peptides do not reproduce any other signs of ocular irritation or inflammation. Apparently, none of the peptides studied could, by itself, be the sole mediator of the initial ocular irritative response although some of them may account for the miosis and contribute to the ocular hypertension associated with this response. A combination of some of these peptides together with I and(or) other prostaglandins may account for all aspects of the ocular irritative response and for most aspects of the ocular inflammatory response.

AN   1982:211568 CAPLUS
DN   96:211568
TI   A comparison of the miotic and inflammatory effects of biologically active
      polypeptides and prostaglandin E2 on the rabbit eye
AU   Bito, L. Z.; Nichols, R. R.; Baroody, R. A.
CS   Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
SO   Experimental Eye Research (1982), 34(3), 325-37
      CODEN: EXERA6; ISSN: 0014-4835
DT   Journal
LA   English

=> d his

      (FILE 'HOME' ENTERED AT 14:06:58 ON 08 AUG 2006)

      INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
      AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
      CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
      DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:07:14 ON 08 AUG 2006
               SEA ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION
               ----
         1   FILE ADISCTI
        13   FILE BIOSIS
         1   FILE BIOTECHABS
         1   FILE BIOTECHDS
         1   FILE BIOTECHNO
        27   FILE CAPLUS
         3   FILE DDFU
         3   FILE DGENE
         4   FILE DRUGU
        17   FILE EMBASE
        28   FILE IFIPAT
         1   FILE IMSRESEARCH
         6   FILE JICST-EPLUS
        15   FILE MEDLINE

```
          3    FILE PASCAL
          1    FILE PHAR
          1    FILE PROMT
          5    FILE PROUSDDR
          4    FILE SCISEARCH
         15    FILE TOXCENTER
         39    FILE USPATFULL
          4    FILE USPAT2
         25    FILE WPIDS
         25    FILE WPINDEX
          6    FILE DPCI
         59    FILE EPFULL
          1    FILE IMSPATENTS
          5    FILE INPADOC
        139    FILE PCTFULL
L1          QUE ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION
            ---------
```

FILE 'BIOSIS, MEDLINE, EMBASE, USPATFULL, EPFULL, PCTFULL' ENTERED AT
14:10:03 ON 08 AUG 2006
L2   282 S ((PROSTAGLANDIN(W)'E2') OR PGE2) AND (OCULAR(W)HYPERTENSION)
L3   161 S L2 NOT PY>2002
L4   146 DUP REM L3 (15 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 14:11:39 ON 08 AUG 2006
L5   1 S PGE2/CN

FILE 'CAPLUS' ENTERED AT 14:11:58 ON 08 AUG 2006
L6   13 S L5 AND (OCULAR(W)HYPERTENSION)
L7   13 S L6 NOT PY>2002

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	25.22	43.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 14:13:59 ON 08 AUG 2006